AU Patent

AU2021269372A1 — Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-12-16 · 4y expired

What this patent protects

OF THE INVENTION The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO Igene, and methods of using such RNAi agents to inhibit expression of HAO1 and 5 methods of treating subjects having, e.g., PHI. 18252595_1 (GHMatters) P105552.AU.1

USPTO Abstract

OF THE INVENTION The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO Igene, and methods of using such RNAi agents to inhibit expression of HAO1 and 5 methods of treating subjects having, e.g., PHI. 18252595_1 (GHMatters) P105552.AU.1

Drugs covered by this patent

Patent Metadata

Patent number
AU2021269372A1
Jurisdiction
AU
Classification
—
Expires
2021-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.